Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Bvf Partners L.P.
BioCentury | Mar 5, 2025
Emerging Company Profile
Bambusa: Combining validated I&I targets in bispecifics to broaden efficacy
With $105M in venture funding, Bambusa has moved quickly towards the clinic with bispecifics in-licensed from antibody powerhouse Biotheus
BioCentury | Oct 15, 2024
Management Tracks
Jonathan Dickinson at the helm of Innate
Plus: Sernova hires CFO and updates from Inventiva
BioCentury | Feb 24, 2022
Finance
Fresh off Amgen deal, Plexium raises $102M for degrader platform
BVF Partners, TCG Crossover co-lead funding to advance Plexium’s cell- and DEL-based degrader discovery tech
BioCentury | Oct 21, 2021
Finance
Oct. 20 Quick Takes: Perceptive’s LianBio aiming for $325M IPO
ShouTi debuts with $158M, plus Saama, Chase, Novavax and more
BioCentury | Jul 14, 2021
Deals
July 13 Quick Takes: Ionis gains oligonucleotide delivery tech from Bicycle; plus Nimbus, ISA and more
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) exercised its option to license from Bicycle Therapeutics Inc. (NASDAQ:BCYC) tissue -targeted delivery vehicles for oligonucleotide therapeutics that use a
BioCentury | Feb 16, 2021
Emerging Company Profile
Medicxi, blue chip investors launch Centessa with $250M to take asset-centric companies further
Emerging Company Profile: newco to bring asset-centricity to pharma scale
BioCentury | Jan 6, 2021
Product Development
Propelled by Ionis deal, Aro raises $88M series A to advance targeted oligo pipeline
J&J spinout readying first two Centyrin-oligo conjugates for the clinic
BioCentury | Oct 19, 2020
Finance
How Nimbus’ focus on internal pipeline could point to long-awaited exit
BioCentury | Sep 4, 2020
Product Development
Rain to advance growing precision oncology pipeline with $63M series B
A crossover-heavy $63 million series B round will provide Rain with enough money to bring what it says is its new lead program — a newly licensed cancer therapy from Daiichi Sankyo —
Items per page:
1 - 10 of 15